Skip to content

Pulmonx Corporation LUNG Inventory write-downs

Inventory write-downs at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$485K
LivaNova logo
LivaNovaLIVN
$0
Inogen logo
InogenINGN
$416K+151%

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-47.3%
Enterprise value$50.17M-43.5%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:InventoryWriteDown.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's inventory write-downs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's inventory write-downs?
Pulmonx Corporation (LUNG) reported inventory write-downs of $144K in Q1 2026.
How has Pulmonx Corporation's inventory write-downs changed year-over-year?
Pulmonx Corporation's inventory write-downs increased by 413.0% year-over-year, from -$46K to $144K.
What is the long-term trend for Pulmonx Corporation's inventory write-downs?
Over 2 years (2021 to 2025), Pulmonx Corporation's inventory write-downs has grown at a -65.3% compound annual growth rate (CAGR), from $1.19M to $143K.
What does inventory write-downs mean?
This represents the adjustment to the carrying value of inventory when the cost of items exceeds their net realizable value. It reflects losses due to obsolescence, physical damage, or market price declines, indicating potential inefficiencies in supply chain management or product demand forecasting. Frequent or large write-downs suggest poor inventory turnover and potential risks to future gross margins.